Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas

Luigi Maria Larocca, Roberto Pallini, Ruggero De Maria Marchiano, Gerardo Battaglia, C. Ciceroni, M. Bonelli, E. Mastrantoni, C. Niccolini, M. Laurenza, A. Traficante, P. Spinsanti, L. Ricci-Vitiani, A. Arcella, F. Nicoletti, G. Battaglia, D. Melchiorri

Risultato della ricerca: Contributo in rivistaArticolo in rivista

40 Citazioni (Scopus)

Abstract

Drug treatment of malignant gliomas is limited by the intrinsic resistance of glioma stem cells (GSCs) to chemotherapy. GSCs isolated from human glioblastoma multiforme (GBM) expressed metabotropic glutamate receptors (mGlu3 receptors). The DNA-alkylating agent, temozolomide, killed GSCs only if mGlu3 receptors were knocked down or pharmacologically inhibited. In contrast, mGlu3 receptor blockade did not affect the action of paclitaxel, etoposide, cis-platinum, and irinotecan. mGlu3 receptor blockade enabled temozolomide toxicity by inhibiting a phosphatidylinositol-3-kinase/nuclear factor-κB pathway that supports the expression of O 6 -methylguanine-DNA methyltransferase (MGMT), an enzyme that confers resistance against DNA-alkylating agents. In mice implanted with GSCs into the brain, temozolomide combined with mGlu3 receptor blockade substantially reduced tumor growth. Finally, 87 patients with GBM undergoing surgery followed by adjuvant chemotherapy with temozolomide survived for longer time if tumor cells expressed low levels of mGlu3 receptors. In addition, the methylation state of the MGMT gene promoter in tumor extracts influenced survival only in those patients with low expression of mGlu3 receptors in the tumor. These data encourage the use of mGlu3 receptor antagonists as add-on drugs in the treatment of GBM, and suggest that the transcript of mGlu3 receptors should be measured in tumor specimens for a correct prediction of patients' survival in response to temozolomide treatment. © 2013 Macmillan Publishers Limited All rights reserved.
Lingua originaleEnglish
pagine (da-a)396-407
Numero di pagine12
RivistaCell Death and Differentiation
Volume20
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • Amino Acids
  • Animals
  • Antineoplastic Agents, Alkylating
  • Cell Biology
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • DNA Methylation
  • Dacarbazine
  • Drug Resistance, Neoplasm
  • Glioblastoma
  • Humans
  • MGMT
  • Mice
  • Molecular Biology
  • NF-kappa B
  • Neoplastic Stem Cells
  • O(6)-Methylguanine-DNA Methyltransferase
  • Phosphatidylinositol 3-Kinases
  • Promoter Regions, Genetic
  • RNA, Messenger
  • Receptors, Metabotropic Glutamate
  • Signal Transduction
  • Survival Rate
  • Transplantation, Heterologous
  • Tumor Cells, Cultured
  • Xanthenes
  • cancer stem cells
  • glioblastoma
  • metabotropic glutamate receptor mGlu3
  • temozolomide

Fingerprint

Entra nei temi di ricerca di 'Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas'. Insieme formano una fingerprint unica.

Cita questo